Mr. Hugh MacNaught reports

VENTRIPOINT TO LAUNCH REFERENCE SITE PROGRAMME TO DEEPEN COLLABORATIONS WITH HOSPITAL PARTNERS

Ventripoint Diagnostics Ltd. has launched its new reference site program. This initiative aims to foster collaboration with key stakeholders in major hospitals to enhance the accuracy, efficiency and diagnostic capabilities of echocardiography.

By engaging with health care professionals at the forefront of cardiac care, Ventripoint seeks to continue to gain invaluable insights into the clinical needs and challenges faced in everyday practice. This collaborative approach will enable the company to continuously improve VMS+ to meet the evolving demands of the health care landscape and deliver optimal patient outcomes.

Ventripoint is currently in discussions with candidate sites and over the next few months will announce the institutions and further information regarding the scope of these relationships.

The reference site program will provide participating hospitals with early access to VMS+ technology, expert training and continuing support. Ventripoint is committed to working closely with these partners to ensure the successful implementation and utilization of VMS+ within their routine clinical workflows. Partner sites will provide greater local visibility of the capabilities of VMS+ and enable more effective peer-to-peer communication regarding adoption of the technology.

"Working closely with clinical experts has been core to everything we do at Ventripoint since the company's founding at the University of Washington," said Ventripoint's chief executive officer, Hugh MacNaught. "The reference site program brings us closer to renowned centres of cardiac excellence in the United States, Europe, the U.K. and Canada. It will provide the opportunity for us to expand applications of our technology to new patient groups and demonstrate value-in-use through more timely treatment decisions and improved patient outcomes."

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.